UroGen Pharma announced strategic collaboration and investment agreements with IntraGel Therapeutics, Ltd., a Nazareth, Israel-based biotech, giving UroGen access to IntraGel’s biodegradable, sustained-release SRGel platform and an option to acquire worldwide rights to IntraGel’s lead candidate, TumoCure, once it completes a Phase 2 clinical study. UroGen will also invest up to $7 million in IntraGel’s equity securities in a related agreement. CEO Liz Barrett framed the deal as a deliberate pipeline expansion: “This Option Agreement represents an important step in expanding UroGen’s oncology pipeline and technological capabilities. IntraGel’s biodegradable, sustained-release technology complements our expertise in local drug delivery while creating significant optionality for future innovation. Beyond the opportunity to advance TumoCure following a Phase 2 clinical study, we believe the SRGel technology could potentially enable multiple therapeutic approaches across a range of solid tumors and provide a foundation for new product opportunities over time.” IntraGel CEO and co-founder Dr. Peter Siman called the partnership a validation of his company’s science: “UroGen’s leadership in localized oncology therapies and commercial-stage experience make them an ideal partner to help advance the SRGel platform and accelerate the development of TumoCure. We see in this collaboration an important validation of the SRGel platform and the clinical potential of our lead product candidate, TumoCure, while creating a strong pathway to accelerate development across multiple oncology indications.”
What UroGen Is Actually Getting
The agreement gives UroGen a research license and exclusive options to develop up to three additional oncology products built on IntraGel’s SRGel platform, a biodegradable depot technology designed to deliver drugs locally and directly into solid tumors over a sustained period. Separately, UroGen holds an exclusive option to acquire worldwide rights to TumoCure specifically, IntraGel’s investigational cisplatin formulation, once IntraGel finishes a Phase 2 clinical study. That structure lets UroGen wait for more clinical evidence on TumoCure specifically while still locking in broader access to the underlying delivery platform now.
How Early TumoCure Actually Is
TumoCure is designed for patients with locally advanced, inoperable head and neck cancers who are ineligible for standard systemic cisplatin-based chemoradiation, delivering the chemotherapy locally with the goal of prolonged local exposure and minimal systemic side effects. It’s worth being clear about how early-stage this still is: the only clinical data available comes from a Phase 1b study presented at the 2026 ASCO Annual Meeting, and according to independent analysis, that data set covers just eight patients, showing safety, tolerability, and early anti-tumor activity, but on a scale far too small to draw firm conclusions. TumoCure is now considered Phase 2-ready, and UroGen’s option to acquire it doesn’t trigger until that larger study is complete.
Why UroGen Is Making This Move Now
UroGen built its business around RTGel, a proprietary reverse-thermal hydrogel platform behind its two approved products: JELMYTO, for low-grade upper tract urothelial cancer, and ZUSDURI, approved in June 2025 as the first medication specifically for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. This IntraGel deal represents UroGen’s first real step toward applying its local-delivery expertise outside urothelial cancer entirely. Financially, the move looks manageable rather than strained: UroGen reported cash, cash equivalents, and marketable securities of $108.0 million as of June 30, 2026, making the $7 million investment a modest near-term outlay rather than a stretch.
A Deal With Limited Regional Ties
Unlike many of the companies this publication covers, this particular deal doesn’t have a strong Greater Philadelphia or BioHealth Capital Region connection to point to. UroGen is headquartered in Princeton, New Jersey, which sits within the broader Philadelphia-to-New York pharmaceutical corridor but isn’t typically considered part of Greater Philadelphia proper, and IntraGel is based in Nazareth, Israel. It’s included here as a relevant regional-adjacent pipeline story rather than one rooted directly in the region’s own life sciences ecosystem.
